Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis | Annals of the Rheumatic Diseases

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

Psoriatic arthritis

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

Online download statistics by month:

Online download statistics by month: March 2022 to March 2024

	Abstract	Full	Pdf
Mar 2022	4193	2541	983
Apr 2022	2461	1700	1649
May 2022	2305	1573	639
Jun 2022	2322	1618	491
Jul 2022	1240	1058	323
Aug 2022	1159	1150	357
Sep 2022	1778	1750	428
Oct 2022	1536	1476	366
Nov 2022	1485	1443	405
Dec 2022	1723	1232	596
Jan 2023	1188	1087	438
Feb 2023	1174	1128	302
Mar 2023	1888	1810	409
Apr 2023	1267	1214	354
May 2023	1285	1250	249
Jun 2023	976	946	222
Jul 2023	694	667	189
Aug 2023	500	486	191
Sep 2023	685	652	261
Oct 2023	782	726	299
Nov 2023	1168	1114	289
Dec 2023	611	544	235
Jan 2024	331	291	125
Feb 2024	547	507	209
Mar 2024	723	704	235
Total	34021	28667	10244